Site Search

Share

X

Search Results

Increasing Access to Biomarker Testing - SB496 (Limón)

Summary: SB 496 (Limón) will increase access to biomarker testing, ensuring patients receive the right treatment at the right time. Need for bill: Precision medicine is dramatically improving cancer outcomes by using information about a person’s own genes or proteins (biomarkers) to prevent, diagnose, or treat disease. Advances in biomarker testing and cancer treatments now allow for targeted cancer therapies that can improve patient survival and quality of life.  Testing ...

Biomarker Testing Is The Key To Precision Medicine

           Precision medicine is changing the way we treat cancer and biomarker testing is the key to opening the door to the types of personalized cancer treatments that can improve survival rates and quality of life. A.1673 and S.1196  requires all state-regulated insurance plans, including Medicaid, to cover biomarker testing when medically appropriate. Read other patients who have benefited from biomarker testing in the New York Biomarker Testing ...

NJ Senate Commerce Committee Advances Biomarker Testing Bill

Earlier today, Senate Bill 3098 was unanimously voted out of the Senate Commerce Committee. This legislation, which aims to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans when patients need it, now advances to the Senate Budget & ... & Insurance Committee approved identical legislation (Assembly Bill 4163), which now awaits a hearing in the Assembly Appropriations Committee. Biomarker testing is a precision medicine tool that utilizes information from patients’ cells to determine the right treatment at the right time ...

House Votes to Remove Barriers to Biomarker Testing

COLUMBUS, OHIO – The Ohio House passed House Bill 24, which would ensure that biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments, is covered by more insurance ... is a statement from Leo Almeida, government relations director for the American Cancer Society Cancer Action Network (ACS CAN) in Ohio: "Biomarker testing and precision medicine are helping extend and improve lives by tailoring care and treatment to a person’s specific type of ...

Health Equity in Biomarker Testing and Targeted Therapy

Despite evidence demonstrating the effectiveness of biomarker testing and targeted therapy, currently not all individuals benefit equitably from these advances. There are notable racial/ethnic, and ... socioeconomic disparities in access and utilization of these advancements in care. These disparities in access and use of guideline-indicated biomarker testing and targeted therapy can potentially widen existing disparities in cancer survival. Health Equity in Biomarker Testing and ...

Hawaii Cancer Advocates Celebrate Passage of Biomarker Testing Resolution

... of HCR 53 during the 2024 legislative session. The resolution moves Hawaii one step closer to advancing legislation to expand access to the testing needed to connect cancer patients and those battling other diseases to precision treatments through biomarker testing . The decision by state legislators coincides with the May 1st release of the American Cancer Society’s first-ever Cancer Facts ... limited, the study can help raise awareness of symptoms and opportunities for prevention, early detection, and treatment.  Increasing access to biomarker testing for Hawaii residents could be a game-changer in connecting cancer patients with the right treatment needed to battle their ...

Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing

Biomarker testing is key to unlocking precision medicine and improving cancer outcomes, however not all individuals are benefiting. In a survey of over 300 oncology providers, 66% reported that insurance coverage for biomarker testing is a moderate or significant barrier to appropriate testing for their patients. Additionally, 91% indicated that they consult clinical ...

Marylanders to Gain Access to Biomarker Testing on Jan. 1

ANNAPOLIS, MD – DECEMBER 20, 2023 – On January 1, 2024, Marylanders will gain access to biomarker testing when Chapter 322 of the Laws of 2023 takes effect for private insurers. The legislation, which requires coverage of biomarker testing when supported by scientific and medical evidence, received near-unanimous support in the Senate and House of Delegates. Governor ...

Maryland Lawmakers Overwhelmingly Support Increasing Access to Biomarker Testing

... passage in the Senate and House of Delegates and representing a victory for cancer patients across Maryland. The legislation aims to ensure biomarker testing is covered by all state-regulated health plans, including Medicaid, when it is supported by medical and scientific evidence. With the Governor’s signature, more Marylanders will benefit from biomarker testing, a critical step in accessing precision medicine services. Dubbed ‘the right treatment at the right time,’ precision medicine ...

The Landscape of Biomarker Testing Coverage in the U.S.

Biomarker testing is becoming increasingly important for cancer care because it connects the right patient, to the right treatment, at the right time, however insurance coverage of testing varies widely. This study, that examines administrative claims data to understand the premium impact of expanding biomarker testing coverage in four markets: commercial self-insured large group, small group, individual, and Medicaid, found a small potential ...

Type

Priority Issue

State

Policy Issue

Judicial Advocacy